CTLA‐4 inhibitor treatment alone did not seem to increase the incidence of pneumonitis, but the incidence of CIP increased when CTLA‐4 inhibitor was combined with PD‐1/PD‐L1 inhibitor. The gene discussed is CTLA4; the disease is hereditary sensory and autonomic neuropathy.